Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cardiovascular risk and sildenafil.

R A Kloner1

  • 1The Heart Institute, Good Samaritan Hospital, Section of Cardiology, University of Southern California, Los Angeles, California, USA.

The American Journal of Cardiology
|July 19, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The assessment of vascular risk in men with erectile dysfunction: the role of the cardiologist and general physician.

International journal of clinical practice·2013
Same author

Emotional stressors trigger cardiovascular events.

International journal of clinical practice·2012
Same author

Bone marrow-derived cell transplantation therapy for myocardial infarction: lessons learned and future questions.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2011
Same author

The endothelial cell in health and disease: its function, dysfunction, measurement and therapy.

International journal of impotence research·2009
Same author

How to save a life during a clinic visit for erectile dysfunction by modifying cardiovascular risk factors.

International journal of impotence research·2009
Same author

Erectile dysfunction and heart failure: the role of phosphodiesterase type 5 inhibitors.

International journal of impotence research·2009

Sildenafil is an effective oral treatment for erectile dysfunction (ED). Cardiovascular risk is low, but it

Area of Science:

  • Cardiovascular Medicine
  • Urology
  • Pharmacology

Background:

  • Erectile dysfunction (ED) is a common condition affecting many men.
  • Oral agents for ED, like sildenafil, primarily work through vasodilation.
  • Cardiovascular interactions are a key consideration for ED pharmacotherapy.

Purpose of the Study:

  • To review the cardiovascular safety and efficacy of sildenafil in men with ED.
  • To assess the risk of adverse cardiovascular events associated with sildenafil use.
  • To provide guidance on patient selection and risk assessment for ED treatments.

Main Methods:

  • Review of clinical trials involving men with ED, with or without cardiovascular conditions.
  • Analysis of cardiovascular adverse events, including myocardial infarction and death.

Related Experiment Videos

  • Evaluation of sildenafil's effect on systemic arterial pressure, particularly with organic nitrates.

    • Main Results:

    • Sildenafil demonstrated efficacy in treating ED across studied populations.
    • No significant increase in serious cardiovascular events, MI, or death was observed compared to placebo.
    • A significant decrease in blood pressure occurs when sildenafil is combined with organic nitrates, making it contraindicated.

    Conclusions:

    • Sildenafil is a safe and effective oral treatment for ED in most patients.
    • Physicians must counsel cardiac patients on the risks of sexual activity and evaluate cardiac status before prescribing ED treatments.
    • Exercise treadmill testing may be beneficial for assessing the safety of sexual activity in patients with coronary artery disease.